DevGen is a biotechnology company that focuses on in vivo drug discovery based on the use of the model organism Caenorhabditis elegans, a small nematode that helps in deeper understanding of human disease and new concepts for therapeutic intervention. The company develops therapies for metabolic and CNS related disease, applies its technologies to mechanism of action studies and has established a programme that enables the high throughput screening of human transmembrane proteins including ion channels and membrane transporters. The company combines the use of model organism biology with powerful assay systems, bioinformatics and project focused chemistry.